Hereditary cancers in gynecology:  What clinicians need to know
Hereditary cancers in gynecology: What clinicians need to knowThe contribution of hereditary cancer syndromes to many gynecologic malignancies has been increasingly recognized over the past decade. As they often serve as primary care providers, ob/gyns are uniquely positioned to help identify at-risk women before they develop cancer.
Genetic testing in oncology: 5 things payers should knowAs genomics continues to evolve, here are five things to know about genetic testing and counseling.
Failure to recommend genetic testing in breast cancerIs this the next wave of medical professional liability lawsuits?
Who is being tested for BRCA?A study looks at who is being tested for BRCA mutations as testing becomes more common. Also, a look at the impact of Zika virus on birth defects using benchmark data. Plus: How is the United States doing with infant mortality?
Biomarkers: Top challenges and opportunities in managed careBiomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.
Beyond BRCA: Promising results with multigene testing for breast cancerResults of a multi center observational study suggest that testing for a panel of genes may be the wave of the future for hereditary breast and ovarian cancer and alter the course of clinical management.
Update on BRCA and ovarian cancerWhat are the current recommendations for managing women who are BRCA 1 or 2 carriers?
Ovarian cancer drug receives accelerated approvalAn ADP-ribose polymerase (PARP) inhibitor has received accelerated approval from the US Food and Drug Administration (FDA) for treatment of women with heavily pretreated ovarian cancer associated with defective BRCA genes.
Agent active in PCa patients with BRCA mutationsIn what is being called the largest clinical trial to examine the efficacy of poly(ADP-ribose) polymerases (PARP) inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced forms of both prostate and pancreatic cancer.
Medical Economics Weekly - New HIPAA rules increase your liability[VIDEO] This episode: more liability with HIPAA rules, a Google Glass hack for doctors, more house calls, Angelina Jolie's doctor, and more.